J Steven Leeder
Overview
Explore the profile of J Steven Leeder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
186
Citations
4694
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Randell R, Gelineau-Morel R, Thomas S, Gonzalez D, Leeder J, Hornik C
J Clin Pharmacol
. 2024 Nov;
65(3):389-395.
PMID: 39535328
The limited number of researchers with expertise necessary toaddress treatment gaps for children presents an ongoing challenge. The NationalInstitutes of Health established a national Pediatric Clinical Pharmacology T32Training Program in...
2.
Parvez M, Thakur A, Mehrotra A, Stancil S, Pearce R, Basit A, et al.
Clin Pharmacol Ther
. 2024 Jul;
116(4):1090-1099.
PMID: 38955794
The expression of cytochrome P450 (CYP) enzymes is highly variable and associated with factors, such as age, genotype, sex, and disease states. In this study, quantification of metronidazole metabolizing CYP...
3.
Ontogeny of Human Liver Aldehyde Oxidase: Developmental Changes and Implications for Drug Metabolism
Subash S, Singh D, Ahire D, Khojasteh S, Murray B, Zientek M, et al.
Mol Pharm
. 2024 May;
21(6):2740-2750.
PMID: 38717252
Despite the increasing importance of aldehyde oxidase (AO) in the drug metabolism of clinical candidates, ontogeny data for AO are limited. The objective of our study was to characterize the...
4.
Thakur A, Yue G, Ahire D, Mettu V, Al Maghribi A, Ford K, et al.
Clin Pharmacol Ther
. 2024 May;
116(1):235-246.
PMID: 38711199
Cross-species differences in drug transport and metabolism are linked to poor translation of preclinical pharmacokinetic and toxicology data to humans, often resulting in the failure of new chemical entities (NCEs)...
5.
Kyler K, Gaedigk A, Abdel-Rahman S, Staggs V, Pearce R, Toren P, et al.
Clin Transl Sci
. 2024 Apr;
17(4):e13782.
PMID: 38629502
In this brief report, we provide an analysis of the influence of a novel CYP2C haplotype (CYP2C:TG) on proton pump inhibitor (PPI) pharmacokinetics (PK) in children. The CYP2C:TG haplotype has...
6.
Wagner J, Abdel-Rahman S, Raghuveer G, Gaedigk A, Boone E, Gaedigk R, et al.
Genes (Basel)
. 2024 Jan;
15(1).
PMID: 38254988
This clinical study examined the influence of c.521T>C (rs4149056) on plasma atorvastatin concentrations in pediatric hypercholesterolemia. The participants (8-21 years), including heterozygous (c.521T/C, n = 13), homozygous (c.521C/C, n =...
7.
Cheng S, Al-Kofahi M, Leeder J, Brown J
Clin Pharmacol Ther
. 2023 Dec;
115(5):1033-1043.
PMID: 38117180
Atomoxetine (ATX) is a non-stimulant used to treat attention-deficit/hyperactivity disorder (ADHD) and systemic exposure is highly variable due to polymorphic cytochrome P450 2D6 (CYP2D6) activity. The objective of this study...
8.
Zubiaur P, Leeder J, Abad-Santos F, Gaedigk A
Clin Pharmacol Ther
. 2023 Nov;
115(2):184.
PMID: 37970726
No abstract available.
9.
Stancil S, Pearce R, Staggs V, Leeder J
Drug Metab Dispos
. 2023 Sep;
51(12):1578-1582.
PMID: 37735064
Scaling factors are necessary for translating in vitro drug biotransformation data to in vivo clearance values in physiologically-based pharmacokinetic modeling and simulation. Values for microsomal protein per gram of liver...
10.
Zubiaur P, Soria-Chacartegui P, Boone E, Prasad B, Dinh J, Wang W, et al.
Clin Pharmacol Ther
. 2023 Aug;
114(5):1033-1042.
PMID: 37528442
A novel haplotype composed of two non-coding variants, CYP2C18 NM_000772.3:c.*31T (rs2860840) and NM_000772.2:c.819+2182G (rs11188059), referred to as "CYP2C:TG," was recently associated with ultrarapid metabolism of various CYP2C19 substrates. As the...